Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China; Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary and Pancreatic Diseases of Hubei Province, Hubei, PR China.
Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China; Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary and Pancreatic Diseases of Hubei Province, Hubei, PR China.
Trends Mol Med. 2023 Oct;29(10):859-872. doi: 10.1016/j.molmed.2023.07.001. Epub 2023 Jul 22.
Non-alcoholic fatty liver disease (NAFLD) is becoming the most important risk factor for hepatocellular carcinoma (HCC). Understanding the progression of benign diseases to HCC is crucial for early prevention and reversal of malignant transformation. Alternative splicing (AS) of RNA plays a role in the pathogenicity, initiation, and transformation of liver disease. We summarize the changes or mutations in the activity of splicing factors in NAFLD and HCC, as well as the impact of AS mediated by epigenetic modifications such as DNA methylation, RNA methylation, histone modification, and protein phosphorylation on liver cell fate. We also summarize therapeutic methods and drugs that are helpful for treating NAFLD, HCC, and the early stages of NAFLD progression to HCC.
非酒精性脂肪性肝病（NAFLD）正成为肝细胞癌（HCC）的最重要危险因素。了解良性疾病向 HCC 的进展对于早期预防和逆转恶性转化至关重要。RNA 的可变剪接（AS）在肝病的发病机制、起始和转化中起作用。我们总结了在 NAFLD 和 HCC 中剪接因子活性的变化或突变，以及 DNA 甲基化、RNA 甲基化、组蛋白修饰和蛋白磷酸化等表观遗传修饰介导的 AS 对肝实质细胞命运的影响。我们还总结了有助于治疗 NAFLD、HCC 和 NAFLD 向 HCC 进展早期阶段的治疗方法和药物。
